Skip to Main Content

Paper Details

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Nature Medicine
16
2022
Glucagon receptor, HbA1c, Hyperglucagonemia, T1D, Volagidemab, cholesterol, glucagon, glucose, hemoglobin A1c, hyperglycemia, hypoglycemia, hypoglycemic, insulin, low-density lipoprotein (LDL)-cholesterol, monoclonal glucagon receptor, participants, patients, type 1 diabetes, volagidemab

Datasets

Release 1.2